Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in R/R Marginal Zone Lymphoma (MAGNOLIA)
NCT03846427Phase 2Completed
- Sponsor
- BeiGene
- Start
- Feb 2019
- Primary completion
- May 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 9
01
Overview
A Phase 2 trial of zanubrutinib in marginal zone lymphoma (MZL), sponsored by BeiGene. Started Feb 2019; status: completed.
02
Drugs
zanubrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03846427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03846427.